0001003642-18-000077.txt : 20180508 0001003642-18-000077.hdr.sgml : 20180508 20180508160659 ACCESSION NUMBER: 0001003642-18-000077 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180504 FILED AS OF DATE: 20180508 DATE AS OF CHANGE: 20180508 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BISARO PAUL CENTRAL INDEX KEY: 0001237253 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34263 FILM NUMBER: 18814563 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Impax Laboratories, LLC CENTRAL INDEX KEY: 0001003642 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 650403311 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 30831 HUNTWOOD AVENUE CITY: HAYWARD STATE: CA ZIP: 94544 BUSINESS PHONE: 510-240-6000 MAIL ADDRESS: STREET 1: 30831 HUNTWOOD AVENUE CITY: HAYWARD STATE: CA ZIP: 94544 FORMER COMPANY: FORMER CONFORMED NAME: IMPAX LABORATORIES INC DATE OF NAME CHANGE: 19991227 FORMER COMPANY: FORMER CONFORMED NAME: GLOBAL PHARMACEUTICAL CORP \DE\ DATE OF NAME CHANGE: 19951117 4 1 wf-form4_152581000589975.xml FORM 4 X0306 4 2018-05-04 1 0001003642 Impax Laboratories, LLC IPXL 0001237253 BISARO PAUL C/O IMPAX LABORATORIES, INC. 30831 HUNTWOOD AVENUE HAYWARD CA 94544 1 1 0 0 President and CEO Stock Option (Right to Buy) 12.7 2018-05-04 4 D 0 850000 D 2027-03-27 Common Stock 850000.0 0 D Options disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017, by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017 (the "BCA"), according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock of Holdco equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA at a per-share exercise price equal to the per-share exercise price of such Option. The filing of this Statement shall not be construed as an admission (a) that the person filing this Statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this Statement, or (b) that this Statement is legally required to be filed by such person. /s/ Wenchi Liu, by Power of Attorney 2018-05-08